Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients

被引：0
作者：
Ranchord, A. M. [1 ]
Harding, S. A. [1 ]
Pidgeon, G. [2 ]
机构：
[1] Wellington Hosp, Dept Cardiol, Wellington 6021, New Zealand
[2] Wellington Hosp, Dept Nephrol, Wellington 6021, New Zealand
来源：
INTERNAL MEDICINE JOURNAL | 2008年 / 38卷 / 05期
关键词：
dialysis; secondary prevention; ischaemic heart disease; left ventricular systolic dysfunction;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We determined the prescription rates of medications for the secondary prevention of ischaemic heart disease and left ventricular systolic dysfunction in stable dialysis patients. In patients with established ischaemic heart disease, statins, beta-blockers and renin-angiotensin-aldosterone system blockers were substantially underprescribed. Furthermore, beta-blockers and renin-angiotensin-aldosterone system blockers were prescribed in less than half of those with left ventricular systolic dysfunction. Contraindications to treatment were infrequent and did not explain these findings.
引用
收藏
页码：361 / U6
页数：4
相关论文
共 11 条
  • [1] Task force 1: The ACCF and AHA codes of conduct in human subjects research
    Adams, RJ
    Antman, EM
    Kavey, REW
    [J]. CIRCULATION, 2004, 110 (16) : 2512 - 2516
  • [2] K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients
    Bolton, K
    Beddhu, S
    Campese, VM
    Chavers, BM
    Cheung, AK
    Churchill, DN
    Goldstein-Fuchs, J
    Herzog, CA
    Henrich, W
    King, K
    Kronenberg, F
    Miholics, BS
    Painter, PL
    Parekh, R
    Roberts, MS
    Stehman-Breen, C
    Stenvinkel, P
    Wali, R
    Weiss, MF
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : S7 - S153
  • [3] Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001
    Chow, FYF
    Polkinghorne, KR
    Chadban, SJ
    Atkins, RC
    Kerr, PG
    [J]. NEPHROLOGY, 2003, 8 (04) : 177 - 183
  • [4] Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy -: A prospective, placebo-controlled trial
    Cice, G
    Ferrara, L
    D'Andrea, A
    D'Isa, S
    Di Benedetto, A
    Cittadini, A
    Russo, PE
    Golino, P
    Calabrò, R
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) : 1438 - 1444
  • [5] FELDMAN AM, 2001, CIRCULATION, V112, P154
  • [6] CLINICAL AND ECHOCARDIOGRAPHIC DISEASE IN PATIENTS STARTING END-STAGE RENAL-DISEASE THERAPY
    FOLEY, RN
    PARFREY, PS
    HARNETT, JD
    KENT, GM
    MARTIN, CJ
    MURRAY, DC
    BARRE, PE
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (01) : 186 - 192
  • [7] Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
    Herzog, CA
    Ma, JZ
    Collins, AJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (12) : 799 - 805
  • [8] Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists
    Martirosyan, HA
    Brass, EP
    Mehrotra, R
    Adler, SG
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (02) : 309 - 321
  • [9] Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients
    Roy, Patrick
    Bouchard, Josee
    Amyot, Robert
    Madore, Francois
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 48 (04) : 645 - 651
  • [10] AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - Endorsed by the National Heart, Lung, and Blood Institute
    Smith, Sidney C., Jr.
    Allen, Jerilyn
    Blair, Steven N.
    Bonow, Robert O.
    Brass, Lawrence M.
    Fonarow, Gregg C.
    Grundy, Scott M.
    Hiratzka, Loren
    Jones, Daniel
    Krumholz, Harlan M.
    Mosca, Lori
    Pasternak, Richard C.
    Pearson, Thomas
    Pfeffer, Marc A.
    Taubert, Kathryn A.
    [J]. CIRCULATION, 2006, 113 (19) : 2363 - 2372
12